ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the …
Over the last 12 months, insiders at ReShape Lifesciences Inc. have bought $0 and sold $39 worth of ReShape Lifesciences Inc. stock.
On average, over the past 5 years, insiders at ReShape Lifesciences Inc. have bought $96,625 and sold $4.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,702 shares for transaction amount of $26,907 was made by STANKOVICH THOMAS (Chief Financial Officer) on 2023‑06‑30.
2024-05-31 | Sale | Chief Financial Officer | 48 0.0002% | $0.25 | $12 | -31.53% | ||
2024-02-29 | Sale | Chief Financial Officer | 43 0.0002% | $0.17 | $7 | +1.33% | ||
2023-12-31 | Sale | Chief Financial Officer | 42 0.0003% | $0.25 | $11 | -31.72% | ||
2023-11-30 | Sale | Chief Financial Officer | 39 0.0003% | $0.23 | $9 | -22.00% | ||
2023-10-25 | Sale | Chief Financial Officer | 131 0.0027% | $0.27 | $35 | -26.00% | ||
2023-10-11 | Sale | Chief Financial Officer | 39 0.0026% | $0.93 | $36 | -28.83% | ||
2023-09-01 | Sale | Chief Financial Officer | 118 0.0034% | $0.89 | $105 | -77.60% | ||
2023-08-24 | Sale | Chief Financial Officer | 39 0.0013% | $1.42 | $55 | -82.09% | ||
2023-08-04 | Sale | Chief Financial Officer | 108 0.0036% | $1.43 | $154 | -84.79% | ||
2023-07-06 | Sale | Chief Financial Officer | 106 0.0064% | $1.47 | $156 | -83.66% | ||
2023-06-30 | Chief Financial Officer | 17,702 1.0643% | $1.52 | $26,907 | -84.10% | |||
2023-05-31 | Sale | Chief Financial Officer | 98 0.0057% | $2.41 | $236 | -89.68% | ||
2023-04-30 | Sale | Chief Financial Officer | 96 <0.0001% | $2.36 | $227 | -64.13% | ||
2023-03-31 | Sale | Chief Financial Officer | 109 <0.0001% | $2.60 | $283 | -85.04% | ||
2023-02-28 | Sale | Chief Financial Officer | 103 <0.0001% | $4.25 | $438 | -76.97% | ||
2023-02-02 | Sale | Chief Financial Officer | 157 <0.0001% | $13.29 | $2,087 | -78.25% | ||
2023-01-24 | Sale | Chief Financial Officer | 158 <0.0001% | $7.49 | $1,183 | -81.24% | ||
2022-12-01 | Sale | Chief Financial Officer | 7,357 0.0335% | $0.15 | $1,112 | -69.71% | ||
2022-11-28 | Sale | Chief Financial Officer | 364,756 1.9555% | $0.17 | $61,826 | -68.05% | ||
2022-11-04 | Sale | Chief Financial Officer | 8,393 0.0385% | $0.27 | $2,287 | -82.14% |
STANKOVICH THOMAS | Chief Financial Officer | 22777 4.4955% | $5.72 | 6 | 33 | +4.59% |
SABBY MANAGEMENT, LLC | 10 percent owner | 1192507 235.3645% | $5.72 | 10 | 0 | |
DOMAIN PARTERS VII L P | 10 percent owner | 813433 160.5468% | $5.72 | 2 | 0 | |
INTERWEST PARTNERS X LP | 10 percent owner | 380224 75.0446% | $5.72 | 2 | 0 | |
Plovanic William J. | President & CEO | 106806 21.0802% | $5.72 | 3 | 0 |